Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20267 Citations
ARA-29011 residuesQEQLERALNSSEach bubble = one amino acid. Size = residue mass. Color = chemical class.ARA-290 (cibinetide) activates the innate repair receptor to drive small nerve fiber regeneration without affecting red blood cell production. Phase 2b trials in sarcoidosis neuropathy showed a 23% increase in corneal nerve fiber area at the 4 mg dose. Research-only; no Phase 3 registered.
1mg · Daily
Summary: Add 2mL BAC water to your 5mg vial. Draw to 40.0 units on a U-100 syringe for a 1mg dose. This vial will last 5 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1mg | Daily |
| Moderate | 2mg | Daily |
| Aggressive | 4mg | Daily |
Reconstitution math first. A 10 mg vial with 2 mL bacteriostatic water gives you 5 mg/mL. At the clinical dose of 4 mg, that's 0.8 mL, or 80 units on a U-100 insulin syringe. One vial lasts 2.5 days at 4 mg/day. You'll need 11 to 12 vials for a full 28-day course. A 5 mg vial with 2 mL BAC water gives 2.5 mg/mL. At 4 mg, that's 1.6 mL per injection, which is too much volume for a comfortable single SC shot. Stick with 10 mg vials if you're running the full clinical dose. Starting at the conservative 1 mg dose? That's 0.2 mL (20 units), and a single 10 mg vial covers 10 days. The 20-minute plasma half-life sounds short, but it's the wrong thing to focus on. ARA-290 clears fast from blood, but the downstream gene expression changes through JAK2/STAT5 persist for hours. Once-daily dosing is sufficient; don't split the dose. Store reconstituted vials at 2 to 8 degrees C. Use within 2 to 3 weeks. Budget before you start. Mid-cycle supply interruption is common and kills the protocol. A clinical-equivalent course at 4 mg/day costs $672 to $1,008 at current research-grade pricing.
Dosing based on Phase 2 trial: ARA-290 in sarcoidosis small fiber neuropathy (2013) — 10 published references.View all sources →
Cross-check your ARA-290 reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
ARA-290 (cibinetide) activates the innate repair receptor to drive small nerve fiber regeneration without affecting red blood cell production. Phase 2b trials in sarcoidosis neuropathy showed a 23% increase in corneal nerve fiber area at the 4 mg dose. Research-only; no Phase 3 registered.
